Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Sponsor: National Cancer Institute (NCI)
This PHASE1 trial investigates Acinar Cell Adenocarcinoma of the Pancreas and Adenocarcinoma of Unknown Primary and is currently completed. National Cancer Institute (NCI) leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Oct 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .